BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Innovations | Mar 25, 2019
Distillery Therapeutics

CD19 CAR T cells for lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Mouse studies suggest CD19-targeted CAR T cells could help treat lupus. In two mouse models of lupus, retro-orbital injection of CD19-targeting CAR T cells decreased the number of CD19-positive...
BC Extra | Mar 7, 2019
Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...
BC Innovations | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
BC Extra | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis....
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BC Innovations | Dec 13, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Ocular hypertension Mouse studies suggest inhibiting CACNA2D1 could help treat ocular hypertension. In a mouse model of ocular hypertension, Lyrica pregabalin, which inhibits CACNAD21, decreased intraocular pressure compared with no treatment. Next steps could...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest an N -carboxyaniline-based selective androgen receptor degrader (SARD) could help treat castration-resistant prostate cancer (CRPC). The SARD is a previously reported N -carboxy-cyanotrifluoromethylaniline analog that binds...
BC Innovations | Dec 20, 2016
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Endocrine In vitro and mouse studies identified a styrylcyclopentenecarbaldehyde-based FGF23 antagonist that could help treat hypophosphatemia. In silico screening of a small molecule library against the N-terminal domain of FGF23 and in vitro testing...
BC Innovations | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis decaprenyl-phosphate N-acetylglucosaminephosphotransferase (rfe; wecA); M. tuberculosis phospho-N-acetylmuramoyl-pentap

Infectious disease INDICATION: Tuberculosis In vitro and cell studies suggest muraymycin D1-based, dual inhibitors of Mycobacterium tuberculosis rfe and murX could help treat tuberculosis (TB). In in vitro enzymatic assays, the antibiotic muraymycin D1 and...
Items per page:
1 - 10 of 46
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Innovations | Mar 25, 2019
Distillery Therapeutics

CD19 CAR T cells for lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Mouse studies suggest CD19-targeted CAR T cells could help treat lupus. In two mouse models of lupus, retro-orbital injection of CD19-targeting CAR T cells decreased the number of CD19-positive...
BC Extra | Mar 7, 2019
Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...
BC Innovations | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
BC Extra | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis....
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BC Innovations | Dec 13, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Ocular hypertension Mouse studies suggest inhibiting CACNA2D1 could help treat ocular hypertension. In a mouse model of ocular hypertension, Lyrica pregabalin, which inhibits CACNAD21, decreased intraocular pressure compared with no treatment. Next steps could...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest an N -carboxyaniline-based selective androgen receptor degrader (SARD) could help treat castration-resistant prostate cancer (CRPC). The SARD is a previously reported N -carboxy-cyanotrifluoromethylaniline analog that binds...
BC Innovations | Dec 20, 2016
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Endocrine In vitro and mouse studies identified a styrylcyclopentenecarbaldehyde-based FGF23 antagonist that could help treat hypophosphatemia. In silico screening of a small molecule library against the N-terminal domain of FGF23 and in vitro testing...
BC Innovations | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis decaprenyl-phosphate N-acetylglucosaminephosphotransferase (rfe; wecA); M. tuberculosis phospho-N-acetylmuramoyl-pentap

Infectious disease INDICATION: Tuberculosis In vitro and cell studies suggest muraymycin D1-based, dual inhibitors of Mycobacterium tuberculosis rfe and murX could help treat tuberculosis (TB). In in vitro enzymatic assays, the antibiotic muraymycin D1 and...
Items per page:
1 - 10 of 46